Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
112.69
+0.59 (+0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
37
38
Next >
2 Stocks Down 75% and 26% to Buy Right Now
November 17, 2022
It's time to go bargain hunting.
Via
The Motley Fool
FDA Outlines Strategy To Review Infant Formula Production Rules
November 16, 2022
Via
Benzinga
7 No-Brainer Blue-Chip Stocks to Buy for 2023 and Beyond
November 12, 2022
With so many troubles ailing the economy and the broader market, investors should focus on these no-brainer blue-chip stocks to buy.
Via
InvestorPlace
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
November 10, 2022
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.9%. Currently, Abbott Laboratories has a...
Via
Benzinga
Better Buy: Johnson & Johnson vs. Abbott Laboratories
November 10, 2022
These two healthcare giants are among the safest stocks investors can buy right now.
Via
The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
November 10, 2022
These healthcare companies haven't been slowed by macroeconomic conditions.
Via
The Motley Fool
3 Reasons to Buy AbbVie Stock Right Now
November 05, 2022
The drugmaker has something to offer to all kinds of investors.
Via
The Motley Fool
Is This Dividend King a Buy Near Its 52-Week Low?
October 28, 2022
Shares of this medical device and diagnostics stock have slumped in 2022.
Via
The Motley Fool
3 Food Processing Dividend Stocks That Could Benefit From Food Shortages Driven By Russia-Ukraine War
November 09, 2022
With global supply chain shortages impacting nearly every sector of the economy in the past two years, will global food shortages worsen? As the U.S.
Via
Benzinga
Got $1,000? 2 Bear Market Stocks to Jump On Right Now
November 08, 2022
Regardless of what the market does next, these top stocks have a much longer growth trajectory ahead.
Via
The Motley Fool
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
November 08, 2022
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines.
Via
The Motley Fool
2 Reasons to Buy DexCom, and 1 Reason to Sell
November 07, 2022
Do the potential benefits outweigh the risks?
Via
The Motley Fool
Edwards Life Sciences Stock Disaster Could Be Your Bounty
November 07, 2022
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.
Via
MarketBeat
Topics
Death
Exposures
COVID-19
Death
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
November 03, 2022
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people.
Via
Benzinga
Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever
November 02, 2022
These healthcare companies should stay relevant for years as they continue to innovate with new products.
Via
The Motley Fool
Is DexCom a Good Healthcare Stock to Buy Now?
November 02, 2022
After rising about 50% in October, investors want to know if this stock still has any fuel in the tank.
Via
The Motley Fool
3 Dividend-Paying Stocks to Buy in November and Hold Forever
November 02, 2022
Adding these stocks to your portfolio could lead to a lifetime of passive income.
Via
The Motley Fool
This Groundbreaking Device Just Keeps Winning for Abbott Labs
November 01, 2022
Its continuous glucose monitor has proven immensely effective in helping type 2 diabetes patients.
Via
The Motley Fool
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
November 01, 2022
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug
Via
MarketBeat
Topics
Economy
Exposures
COVID-19
Interest Rates
Supply Chain
NYSE: ABT Investor Notice: Deadline on October 31, 2022 in Lawsuit Against Abbott Laboratories
October 31, 2022
San Diego, CA -- (SBWIRE) -- 10/31/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 31, 2022 in the lawsuit filed for certain investors of Abbott Laboratories...
Via
SBWire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
October 31, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ABT MONDAY DEADLINE NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
October 29, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
October 28, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Looking Into Abbott Laboratories's Recent Short Interest
October 27, 2022
Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 16.33% since its last report. The company recently reported that it has 13.99 million shares sold short, which is 0.82% of all regular...
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
October 26, 2022
Upgrades
Via
Benzinga
ABT FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
October 24, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
October 22, 2022
Third-quarter results were less than encouraging on the surface, but what do they say about the road ahead for Abbott Laboratories?
Via
The Motley Fool
10 Dividend Kings That May Last Centuries
October 22, 2022
The following 10 Dividend Kings have increased their dividends for at least 50 consecutive years, and stand a good chance of increasing their dividends for another 50 years.
Via
Talk Markets
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
October 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.